找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond; Bernward Garthoff,Andreas M. Knorr,Friedel Seuter Conference

[复制链接]
查看: 46360|回复: 42
发表于 2025-3-21 16:52:57 | 显示全部楼层 |阅读模式
书目名称Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond
编辑Bernward Garthoff,Andreas M. Knorr,Friedel Seuter
视频video
图书封面Titlebook: Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond;  Bernward Garthoff,Andreas M. Knorr,Friedel Seuter Conference
描述At the workshop held in Leverkusen on December 1, 1993, Professor Dr. Stanislav Kazda was honored on the occasion of his retirement for his scientific contributions and his involvement in drug development in our company, Bayer AG. In a recent article by Eugene Garfield (Current ContentslLife Sciences 36:3-15, 1993), what most of us participating in this workshop have supposed for years was confirmed: that Kazda is one of the leading scientific authors in academia worldwide. In the said survey of citations of biomedical research articles, Kazda is number 29 in terms of actual impact, individual ~itations, and total number of published manuscripts (and this only covers the time period from 1981 to 1992). In addition, his work has contributed significantly to the number eight ranking of our company in the so-called Corporation List. With the support of colleagues inside and outside the company, Kazda made a new substance class, the 1, 4-dihydropyridines, discovered by Bossert and Vater, well known to the scientific community on a worldwide basis and established its outstanding usefulness in hypertension. He has contributed numerous publi­ cations on the pharmacology of these calcium a
出版日期Conference proceedings 1995
关键词Calcium antagonists; Calciumantagonisten; Hochdruck; Pharmakologie; Stroke; hypertension; pathophysiology;
版次1
doihttps://doi.org/10.1007/978-3-642-79338-7
isbn_softcover978-3-540-58545-9
isbn_ebook978-3-642-79338-7
copyrightSpringer-Verlag Berlin Heidelberg 1995
The information of publication is updating

书目名称Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond影响因子(影响力)




书目名称Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond影响因子(影响力)学科排名




书目名称Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond网络公开度




书目名称Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond网络公开度学科排名




书目名称Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond被引频次




书目名称Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond被引频次学科排名




书目名称Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond年度引用




书目名称Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond年度引用学科排名




书目名称Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond读者反馈




书目名称Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 20:33:56 | 显示全部楼层
发表于 2025-3-22 02:18:59 | 显示全部楼层
Erich Grießler,Harald Rohracher first argument for the implication of a change in Ca. Channels in hypertension is the blood pressure-lowering effect of dihydropyridine Ca. antagonists (MacGregor et al. 1982; Kazda and Knorr 1990). These antagonists have also been shown to suppress the myogenic active tone displayed by blood vesse
发表于 2025-3-22 07:59:21 | 显示全部楼层
Pharmacogenetic Study in Asthma,histicated preparation far from the physiological State. Therefore, we decided to study this question in anesthetized dogs in which the CA were infused directly into the left renal artery (LRA) at a dose not influencing systemic blood pressure [8]. Nevertheless, the . effects of CA are clinically no
发表于 2025-3-22 12:34:38 | 显示全部楼层
Functional Modifications in Blood Vessels of Hypertensive Rats, first argument for the implication of a change in Ca. Channels in hypertension is the blood pressure-lowering effect of dihydropyridine Ca. antagonists (MacGregor et al. 1982; Kazda and Knorr 1990). These antagonists have also been shown to suppress the myogenic active tone displayed by blood vesse
发表于 2025-3-22 13:22:54 | 显示全部楼层
Influence of Calcium Antagonists on Kidney Function of Hypertensive Rats,histicated preparation far from the physiological State. Therefore, we decided to study this question in anesthetized dogs in which the CA were infused directly into the left renal artery (LRA) at a dose not influencing systemic blood pressure [8]. Nevertheless, the . effects of CA are clinically no
发表于 2025-3-22 20:43:33 | 显示全部楼层
发表于 2025-3-22 21:56:38 | 显示全部楼层
Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond978-3-642-79338-7
发表于 2025-3-23 01:46:20 | 显示全部楼层
发表于 2025-3-23 06:55:15 | 显示全部楼层
Protection Against Hypertensive Tissue Damage,anda of the pharmaceutical industry. In my experience, this sceptical attitude is rather common among critical clinicians. And frankly speaking, from their point of view, such an attitude is fairly well substantiated.
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-31 23:09
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表